Standout Papers

GLP-1 receptor agonists for individualized treatment of type 2 diabetes me... 2008 2026 2014 2020 974
  1. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus (2012)
    Juris J. Meier Nature Reviews Endocrinology
  2. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art (2020)
    Michael A. Nauck, Daniel R. Quast et al. Molecular Metabolism
  3. Incretin hormones: Their role in health and disease (2018)
    Michael A. Nauck, Juris J. Meier Diabetes Obesity and Metabolism
  4. β-Cell Replication Is the Primary Mechanism Subserving the Postnatal Expansion of β-Cell Mass in Humans (2008)
    Juris J. Meier, Alexandra E. Butler et al. Diabetes
  5. Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin (2011)
    Michael A. Nauck, Stefano Del Prato et al. Diabetes Care
  6. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors (2017)
    Michael A. Nauck, Juris J. Meier et al. Circulation
  7. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial (2019)
    Richard E. Pratley, Aslam Amod et al. The Lancet
  8. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions (2016)
    Michael A. Nauck, Juris J. Meier The Lancet Diabetes & Endocrinology
  9. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes (2021)
    Michael A. Nauck, Jakob Wefers et al. The Lancet Diabetes & Endocrinology

Immediate Impact

4 from Science/Nature 134 standout
Sub-graph 1 of 13

Citing Papers

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
2025 Standout
The burden of diseases, injuries, and risk factors by state in the USA, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
2024 Standout
3 intermediate papers

Works of Juris J. Meier being referenced

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
2020 Standout
Role of Reduced β-Cell Mass Versus Impaired β-Cell Function in the Pathogenesis of Type 2 Diabetes
2013
and 7 more

Author Peers

Author Last Decade Papers Cites
Juris J. Meier 11632 7918 5732 205 16.5k
Tina Vilsbøll 14339 7870 6742 447 19.5k
Yutaka Seino 10904 7161 8364 552 21.9k
Eiichi Araki 7382 5642 9268 298 21.0k
Carolyn F. Deacon 14894 8357 6209 232 19.2k
Andrea Mari 9017 6599 4537 281 14.6k
W. Creutzfeldt 8856 9026 4710 400 17.2k
Volker Vallon 6920 4313 8279 241 17.6k
Hirotaka Watada 6241 5134 4703 497 14.4k
Yuichiro Yamada 4943 3636 4642 276 11.4k
Michael B. Wheeler 3888 6511 5944 202 13.2k

All Works

Loading papers...

Rankless by CCL
2026